- Sales -1%, adj. EBITA +1% vs. cons, -6% org. sales - Cons '24e EBITA to come down 2-4% - Slightly ...
Redeye’s view on the Q4 report. The organic growth was way above our and the market’s expectations.
CapMan's Q4 fell short of LSEG Data & Analytics consensus expectations, partly explained by adjustme...
Redeye updates on Embracer ahead of Q3-results (due 15 February) where growth will be driven by the ...
- Sales +5% y-o-y, EBITA +38% y-o-y - We lift '24e-'25e EBITA by 3% on 1% lower opex - 10x '24e EV/E...
Vaisala will report Q4 earnings on February 14th. We expect solid performance in W&E while IM contin...
On Thursday, February 15, Starbreeze will publish its year-end report.
Redeye views the announced large acquisition of Prido as positive and increase both the near-term es...
- We expect 22% organic growth in Q4 and EBIT up 35% y-o-y - 2024e-25e EBIT down 6% as FX shaves 2% ...
CapMan's net sales in Q4 amounted to EUR 14.1m, below our estimates and below consensus (EUR 15.
Redeye updates its view and outlook on Nanologica following the company’s year-end report and announ...
Q4 results Sales SEK 403m (0% vs ABGSCe 403m), EBITDA 71m (6% vs ABGSCe 67m), EBITA 44m (12% vs ABGS...
Redeye continues to be positive to Bredband2 following a solid Q4 report, where a higher-than-expect...
Redeye comments on last night’s news regarding Netmore’s acquisition of Senet, a North American-base...
Redeye reinforces its positive view of CombinedX following a strong Q4 report, with profitability be...
Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and P...
Mesdopetam EOP2 FDA meeting on 20 Feb, feedback 30 days later Pirepemat Ph 2b full enrolment in Q3'2...
Underwhelming performance continues in Q4 EBITA down 7-3%, lower in both segments Share trading at 1...
CapMan reported Q4 EBIT of -4.8m, clearly below Refinitiv consensus at EUR 6m.
Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into...
